TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T06596 XX ID T06596 XX DT 20.05.2005 (created); oke. DT 11.12.2013 (updated); mkl. CO Copyright (C), QIAGEN. XX FA C/EBPbeta-LIP XX SY C/EBP-beta3; C/EBPbeta(p20); LIP; liver inhibitory protein; NF-IL6-3; NF-IL6-3 repressor form. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G002899 CEBPB; HGNC: CEBPB. XX CL C0008; bZIP. XX SZ 147 AA; 15.9 kDa (cDNA) (calc.), 18kDa [3] XX SQ MAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQ SQ VKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVE SQ QLSRELSTLRNLFKQLPEPLLASSGHC XX SC Swiss-Prot#P17676, edited XX FT 71 135 SM00338; brlzneu. FT 72 125 PF07716; bZIP_2. FT 73 136 PS50217; BZIP. XX SF C/EBPbeta-LIP isoform results from the usage of an alternative initiation site at position 199 of the protein sequence of the NF-IL6-1 isoform; SF sequence is identical to the C-terminal 147 AA of the NF-IL6-1 isoform [1]; SF one of the three forms encoded by the human CEBPbeta gene that result from the usage of different in frame AUGs of the same mRNA species [3]; SF the shortest form, lacks the transactivation domain [1] [3]; SF may dimerize with activator isoforms NF-IL6-1,2 and thus function as a repressor [1]; SF bZIP domain of C/EBPbeta-LIP is involved in direct interactions with c-Jun [1]; XX FF repressor form [3]; XX IN T05499 BAF47; human, Homo sapiens. IN T05451 BRG1; human, Homo sapiens. IN T01261 Brm; human, Homo sapiens. IN T00337 GR-alpha; human, Homo sapiens. IN T08321 p53-isoform1; human, Homo sapiens. IN T08628 POU2F1; Mammalia. IN T01661 PR A; human, Homo sapiens. IN T00696 PR B; human, Homo sapiens. IN T22463 SNF2H; human, Homo sapiens. IN T22464 SNF2H; human, Homo sapiens. XX MX M00109 V$CEBPB_01. MX M00117 V$CEBPB_02. MX M07315 V$CEBPB_Q3. MX M01896 V$CEBPB_Q6. MX M00912 V$CEBP_Q2_01. MX M00770 V$CEBP_Q3. XX BS R38635. BS R57760. BS R57763. BS R57764. BS R57852. BS R34771. BS R16777. BS R57796. XX DR TRANSPATH: MO000054455. DR TRANSCOMPEL: C00116. DR TRANSCOMPEL: C00563. DR UniProtKB: P17676-3; XX RN [1]; RE0004730. RX PUBMED: 8264594. RA Hsu W., Kerppola T. K., Chen P.-L., Curran T., Chen-Kiang S. RT Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region RL Mol. Cell. Biol. 14:268-276 (1994). RN [2]; RE0006266. RX PUBMED: 7935377. RA Klampfer L., Lee T. H., Hsu W., Vilcek J., Chen-Kiang S. RT NF-IL6 and AP-1 cooperatively modulate the activation of the TSG-6 gene by tumor necrosis factor alpha and interleukin-1 RL Mol. Cell. Biol. 14:6561-6569 (1994). RN [3]; RE0007308. RX PUBMED: 8455626. RA Hsu W., Chen-Kiang S. RT Convergent regulation of NF-Il6 and Oct-1 synthesis by interleukin-6 and retinoic acid signaling in embryonal carcinoma cells RL Mol. Cell. Biol. 13:2515-2523 (1993). RN [4]; RE0044354. RX PUBMED: 11773445. RA Christian M., Pohnke Y., Kempf R., Gellersen B., Brosens J. J. RT Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells RL Mol. Endocrinol. 16:141-54 (2002). RN [5]; RE0047933. RX PUBMED: 10602039. RA Hatada E. N., Chen-Kiang S., Scheidereit C. RT Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription. RL Eur. J. Immunol. 30:174-184 (2000). RN [6]; RE0048275. RX PUBMED: 16227626. RA Schneider-Merck T., Pohnke Y., Kempf R., Christian M., Brosens J. J., Gellersen B. RT Physical interaction and mutual transrepression between CCAAT/enhancer-binding protein beta and the p53 tumor suppressor. RL J. Biol. Chem. 281:269-278 (2006). RN [7]; RE0068544. RX PUBMED: 18820298. RA Wang W. L., Lee Y. C., Yang W. M., Chang W. C., Wang J. M. RT Sumoylation of LAP1 is involved in the HDAC4-mediated repression of COX-2 transcription. RL Nucleic Acids Res. 36:6066-6079 (2008). XX //